-
Integrated generation and characterization of CAR T cells
Count on connections that turn science into progress: Integrated generation and characterization of CAR T cells, a short video
3:09
-
Paul's Story
When his lymphoma grew faster than expected, Paul Chae was treated with CAR-T cell therapy at Massachusetts General Hospital. This therapy represents a significant step forward in the development of immunotherapies.
3:14
-
GMP cell banks as part of a staged, standardized, platform-style cell production process
This presentation will focus on the “how and why” of integrating high quality ancillary raw materials into cell therapy product development and manufacturing workflow, beginning with the starting cell source and master cell bank.
55:10
-
Cell and Gene Therapy Solutions: Enabling PSC Translation Workflows
Learn about how Thermo Fisher offers consistent reprogramming, defined culture reagents and comprehensive characterization solutions for your iPSCs.
1:05:14
-
Asprer and Sangenario - CTS Essential 8 Medium
Learn about Cell Therapy Systems™ (CTS™) Essential 8™ Medium, a feeder-free pluripotent stem cell (PSC) medium designed to satisfy global regulatory requirements. We detail how CTS Essential 8 Medium reduces risks and facilitates regulatory filings.
51:45
-
Roos and Kime - GMP Ancillary Materials for Cell and Gene Therapy Manufacturing
This webinar will cover regulatory requirements for GMP ancillary materials and the importance of regulatory documentation. The second part of this session will address aspects you should consider now to clear your path to commercial manufacturing.
42:11
-
Physiological Oxygen: Historical and Molecular Perspective for Stem Cell Culture
Review history and advances in oxygen concentration in vivo and how hypoxia-inducible factor-1 modulates the cell’s response; demonstrate these effects on stem cells and primary cells, and how CO2 incubators provide a physiological oxygen environment
29:20
-
Transitioning to the clinic from proof of concept research
Raw materials, processes, and cell banks may all require changes to meet regulatory guidances and more stringent specifications for treating a patient. We will discuss the practical aspects of developing a cell therapy to treat heart disease.
27:09
-
Comparison of Teratoma assay and in vitro surrogate tests for assessment of pluripotency of hPSCs
For optimal use of human induced hiPSCs it is essential to identify lines that are fully reprogrammed and of high quality with proven pluripotency in terms of differentiation. Learn about various characterization methods tested.
18:10
-
Comprehensive characterization of pluripotent stem cells
Here we describe three characterization methods: PluriTest, KaryoStat, and Scorecard.
21:11
- Popular
- Shop All Products
- Services
Thermo Fisher Scientific
United States